Resmetirom's Early Prescribing Patterns Assessed Across 3712 Patients in Multi-Institutional Cohort

Metabolic dysfunction-associated steatohepatitis (MASH), formerly NASH, is a progressive liver disease characterized by steatosis, inflammation, and hepatocyte ballooning, often leading to fibrosis, cirrhosis, and liver failure. Until recently, no FDA-approved pharmacotherapy existed, leaving patients with limited options beyond lifestyle modifications. The recent approval of Resmetirom, a thyroid hormone receptor-beta (THR-β) agonist, marks a significant milestone as the first drug specifically indicated for noncirrhotic MASH with moderate-to-advanced fibrosis. Understanding its early real-world adoption and prescribing trends is crucial for assessing its integration into clinical practice and identifying potential barriers or disparities in access.

This retrospective cohort study leveraged the TriNetX Research Network, a federated database encompassing electronic health records from numerous healthcare organizations. Researchers analyzed data from 3712 patients across 44 healthcare organizations who received Resmetirom prescriptions. The study aimed to characterize the early prescribing patterns of this novel therapy following its FDA approval in March 2024. The primary objective was to assess demographic characteristics and initial trends associated with Resmetirom adoption in a real-world setting, providing insights into its initial integration into clinical practice.